CTLA4 and melanoma: Anti-PD1 and anti-CTLA4 therapies have long been established in the management of melanomas, with multiple landmark studies such as the CheckMate and KEYNOTE studies.79, 80, 81, 82, 83, 84 In our analyses, anti-PD1 demonstrated a clear survival benefit over anti-CTLA4 therapy.